In the heart of the world’s drug pharmacy, a single patent expiry date quietly rewrote the economics of one of the most consequential drug categories on the planet.
Semaglutide, the active molecule behind Novo Nordisk’s blockbuster Ozempic and Wegovy, lost its patent protection in India. Within 48 hours, more than fifteen generic versions had landed in the market. Within weeks, that number is expected to swell past fifty brands from over forty manufacturers, each one a bet that India’s chronic disease crisis represents the next great frontier in pharmaceutical history.
The numbers that frame this moment are staggering. According to the International Diabetes Federation, nearly 90 million adults in India were living with diabetes in 2024, a figure projected to cross 156 million by 2050.
Obesity rates have surged alongside: the ICMR-INDIAB study documented over 254 million adults with generalised obesity. Despite this, the Indian GLP-1 therapy market has remained a relatively niche segment, valued at around Rs 1,400 crore. The reason is simple and brutal. Novo Nordisk priced Ozempic between Rs 8,800 and Rs 11,175 per month, and Wegovy at up to Rs 16,400. In a country where long-term affordability is the central variable in whether patients actually complete a course of treatment, those numbers locked out a vast majority of the people who needed the drug most.
The patent cliff has changed that calculus overnight. Natco Pharma, one of the first movers, is offering its multi-dose vial format at Rs 1,290 per month, a starting price that would have seemed implausible even six months ago. Alkem Laboratories has entered with prefilled injections starting at Rs 1,800. Sun Pharma and Dr Reddy’s are operating at roughly 50% below Novo’s original prices, while smaller domestic players have pushed discounts to 80% and beyond. The scale of this price correction does not merely represent competitive positioning. It is, potentially, the single most significant expansion of access to a metabolic therapy in India’s medical history.
India’s pharmaceutical industry had been preparing for this moment with characteristic precision. Zydus Lifesciences entered into a co-marketing collaboration with Lupin, pairing Zydus’s manufacturing capability with Lupin’s deep distribution network. Natco partnered with Eris Lifesciences for commercial reach. Dr Reddy’s announced plans to launch 12 million pens in its first year, with an eye on 87 markets globally as semaglutide patents begin to fall in other countries through 2026 and beyond.
Mankind Pharma, targeting smaller cities and towns under its Samakind brand, is competing not just on price but on geography, aiming to reach patient populations that premium branded products never reached at all. Torrent Pharma has gone further still, introducing an oral semaglutide formulation, a potentially significant differentiator in a market where patient hesitancy around injections remains a real clinical barrier.
Novo Nordisk is not conceding the field. The Danish company cut Wegovy’s price by 37% in November 2025, ahead of the patent expiry, and has since repositioned its branded products through local partnerships. Wegovy is being marketed as Poviztra through Emcure Pharma, and Ozempic as Extensior via Abbott India, both companies with deep-rooted physician and pharmacy relationships.
Vikrant Shrotriya, managing director of Novo Nordisk India, framed the strategy in terms of ecosystem value rather than price competition. The company is betting on clinical credibility, brand trust, and patient support infrastructure as the features that justify a continuing premium. Whether that moat holds in a market about to be flooded with fifty brands remains the defining question.
The risks that accompany this opening are real and worth naming. Healthcare consultant Salil Kallianpur, speaking to Reuters, warned that falling prices and a proliferation of brands could give rise to direct pharmacy purchases without physician oversight, off-label use in urban lifestyle markets, poor dosage titration, and ultimately unmanaged side effects that damage patient outcomes and invite regulatory backlash.
Not all generic versions have received approval for both diabetes and obesity indications. Some are cleared for diabetes management alone, meaning real-world prescribing patterns and formal regulatory positioning may quickly diverge.
The broader significance of what India is experiencing is not lost on global observers. Semaglutide will not face generic competition in the United States until 2032, and European patent protection runs to a similar horizon. India has effectively become the proving ground for what a post-patent GLP-1 market looks like.
Analysts at Jefferies project the Indian semaglutide segment could grow to nearly Rs 12,000 crore by 2030. If the country can absorb this transition without a quality and safety crisis, it will have written a template that the rest of the developing world will follow as patents expire in Brazil, China, Canada, and Turkey through this decade.
India has long carried the title of the world’s pharmacy. This week, it is filling a prescription of its own.
